help button home button Endocrine Society Endocrine Reviews
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First published online on April 6, 2005
Endocrine Reviews, doi:10.1210/er.2004-0018
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/3/393    most recent
Final Manuscript
Author Manuscript
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, R.-C.
Right arrow Articles by O’Malley, B. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, R.-C.
Right arrow Articles by O’Malley, B. W.
Endocrine Reviews 26 (3): 393-399
Copyright © 2005 by The Endocrine Society

Transcriptional Regulation by Steroid Receptor Coactivator Phosphorylation

Ray-Chang Wu, Carolyn L. Smith and Bert W. O’Malley

Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas 77030

Correspondence: Address all correspondence and requests for reprints to: Carolyn L. Smith, Ph.D., Molecular and Cellular Biology, One Baylor Plaza, Houston, Texas 77030. E-mail: carolyns{at}bcm.tmc.edu


   Abstract
Top
 Abstract
I. Introduction
 II. Coactivator Phosphorylation...
 III. Cellular Signaling,...
 IV. Concluding Remarks
 References
 
The basic mechanisms underlying ligand-dependent transcriptional activation by nuclear receptors (NRs) require the sequential recruitment of various coactivators. Increasing numbers of coactivators have been identified in recent years, and both biochemical and genetic studies demonstrate that these coactivators are differentially used by transcription factors, including NRs, in a cell/tissue type- and promoter-specific manner. However, the molecular basis underlying this specificity remains largely unknown. Recently, NRs and coregulators were shown to be targets of posttranslational modifications activated by diverse cellular signaling pathways. It is argued that posttranslational modifications of these proteins provide the basis for a combinatorial code required for specific gene activation by NRs and coactivators, and that this code also enables coactivators to efficiently stimulate the activity of other classes of transcription factors. In this review, we will focus on coactivators and discuss the recent progress in understanding the role of phosphorylation of the steroid receptor coactivator family and the potential ramifications of this posttranslational modification for regulation of gene expression.

I. Introduction
A. Nuclear receptors (NRs) and coregulators
B. SRC family of coactivators: molecular structure and biological functions

II. Coactivator Phosphorylation as the Molecular Basis for Coactivator Specificity
III. Cellular Signaling, Coactivator Phosphorylation, and Cancer
IV. Concluding Remarks


   I. Introduction
Top
 Abstract
 I. Introduction
II. Coactivator Phosphorylation...
 III. Cellular Signaling,...
 IV. Concluding Remarks
 References
 
A. Nuclear receptors (NRs) and coregulators
STEROID RECEPTORS ARE part of the superfamily of NRs, which are transcription factors that regulate expression of numerous biologically important target genes; in the case of steroid receptors, transcriptional activity is regulated by steroid hormones (1). Collectively, the functions of NRs are required for a wide variety of important biological processes, including homeostasis, organogenesis, development, and reproduction. Structurally, NRs can be divided into several signature functional domains (1, 2). These include, from the amino to the carboxyl terminus, the first activation function (AF-1) domain, the DNA-binding domain, the hinge region, and the ligand-binding domain that also contains the second activation function (AF-2) domain.

Functionally, the full activity of NRs depends on a large number of cellular factors that do not bind DNA directly but are otherwise recruited to the promoters by NRs. These cellular proteins are collectively defined as coregulators. Depending on the effect of the coregulators on the outcome of gene expression, they can be broadly divided into coactivators that promote NR activation of transcription, and corepressors that suppress NR-dependent gene expression. In recent years, we have witnessed not only the identification of increasing numbers of coregulators, but also the achievement of a better understanding of the molecular basis by which these coregulators function. However, it is not the intention of this review to discuss in detail the role of coactivators or corepressors in NR function and, for this matter, readers are referred to several excellent recent reviews (3, 4). Instead, we will focus only on the p160 steroid receptor coactivator (SRC) family of coactivators, particularly on SRC-3, and discuss novel and interesting aspects of its diverse cellular biology.

B. SRC family of coactivators: molecular structure and biological functions
SRC-3 [also referred to as acetyltransferase/p300/cAMP response element binding protein (CREB)-binding protein (CBP)-interacting protein/receptor-associated coactivator 3/thyroid hormone receptor-activated molecule 1/amplified in breast cancer 1 (AIB1)] is one of the three members of the SRC (p160) family of coactivators. Structurally, all three SRCs (SRC-1/nuclear receptor coactivator-1, SRC-2/transcriptional intermediary factor 2/glucocorticoid receptor interacting protein 1/nuclear receptor coactivator-2, and SRC-3) contain a so-called basic helix-loop-helix-Per/ARNT/Sim domain at their amino termini, which is also the most conserved region among the SRCs (reviewed in Refs. 5 and 6). The basic helix-loop-helix-Per/ARNT/Sim domain was originally identified in Drosophila proteins, where it was shown to be involved in DNA binding and mediating protein-protein interactions (7). Because SRCs also contain this well-defined domain, it is reasonable to envision that cross-talk between different pathways involving SRCs might occur through interactions of this domain of SRCs with other proteins. In fact, members of the SRC family have been shown to interact with myogenin, MEF-2 C, and transcriptional enhancer factor (TEF) through this domain (8, 9). Moreover, the ability of SRCs to coactivate with other transcription factors, such as nuclear factor-{kappa}B (NF-{kappa}B), activator protein 1 (AP-1), signal transducers and activators of transcription (STAT), p53 and E2F1, suggests that SRCs are important components of multiple pathways (10, 11, 12, 13, 14, 15). In fact, different regions of SRCs were shown to be responsible for the interactions of p160s with these factors, further emphasizing the flexibility available to these coactivators to modulate the activity of various classes of transcription factors (10, 12, 16, 17, 18) (Fig. 1Go). These findings clearly suggest that SRCs may be more versatile coactivators, relative to their functional interactions with more diverse transcription factors, than was originally understood.



View larger version (15K):
[in this window]
[in a new window]
  		FIG. 1. Schematic diagram of the common structural and functional domains of SRC family of coactivators. The lines above the bar identify the regions containing conserved structural and functional features among SRCs. These include: the basic-helix-loop-helix/Per/ARNT/Sim (bHLH/PAS); the serine/threonine-rich regions (S/T); the LXXLL motifs responsible for interaction with nuclear receptors (RID); the intrinsic transcription activation domains of SRCs (AD1 and AD2); the glutamine-rich regions (Q); and the HAT domain identified in SRC-1 and SRC-3. The lines under the bar indicate regions that are responsible for interaction with transcription factors or other coregulators. MEF, Myocyte enhancer factor-2C; TEF, transcriptional enhancer factor; RID, receptor-interacting domain. (Note: not drawn to scale).

 
A centrally located region of the SRCs contains multiple LXXLL motifs (where L is leucine and X is any amino acid) that are responsible for ligand-dependent interaction with NRs (19, 20, 21). These motifs also are known as NR boxes. Further carboxy-terminal to the NR-interaction domain of SRCs is a region that was shown to contain the intrinsic transcriptional activation domain (19, 22). This domain also coincides with the region responsible for interaction of SRCs with the histone acetyltransferase activity (HAT)-containing p300/CBP cointegrators, and this interaction is shown to be critical for transcription activation mediated by SRCs (20, 23, 24). Additional functions of the carboxyl termini of SRCs are to bind other coactivators such as the coactivator-associated arginine methyltransferase-1 (CARM1) (25), and to provide intrinsic HAT activity in SRC-1 and SRC-3 (25, 26). The preponderance of intrinsic or associated enzymatic activities that can modify histone proteins suggests that chromatin modification by SRC coactivators, either directly or indirectly, is important for their transcriptional activity. Based on the presence of these important domains, it also has been suggested that the p160/SRC family of coactivators serve as adaptor molecules to recruit additional coactivators and basal transcription machinery to the promoter. In support of this, SRCs have been shown to synergistically activate NR activity in conjunction with p300/CBP and CARM1 in transient transfection assays (25, 27, 28, 29). Conversely, inhibition of p160 coactivator expression by small interfering RNAs or antisense oligonucleotides attenuates ligand-induced target gene expression (30, 31).

Recently, the biological functions of SRCs in vivo have been revealed by gene disruption experiments in mice. Mice lacking SRC-1 showed normal growth and fertility but displayed partial resistance to multiple steroid hormones (32). SRC-2–/– mice also exhibit normal growth, but have reduced fertility in both males and females due to gonadal failure (33). Additionally, SRC-2 null mice are leaner and contain less white adipose tissue but more active brown adipocytes (34). In stark contrast to SRC-1 and SRC-2 null mice, knockout of SRC-3 results in growth retardation and smaller body size (35, 36). SRC-3-null mice also display resistance to growth hormones and estrogen. Interestingly, although knockouts of each individual SRC did not result in embryonic lethality, likely due to some functional coactivator redundancy among family members, the mice clearly exhibited distinct phenotypic defects, suggesting the presence of unique functions for each of these family members. For a more detailed discussion of the phenotypes of the SRC null mice, readers are referred to a recent review by Xu and Li (6).

Despite substantial progress in our understanding of the importance of SRCs, many intriguing and physiologically relevant questions remain unanswered. In this review, we will explore posttranslational modifications of SRCs, particularly with emphasis on SRC-3 phosphorylation, as a novel type of regulation of the transcriptional activity of coactivators. We will discuss the involvement of phosphorylation in the determination of transcription factor specificity and the potential implications of phosphorylation in tumorgenesis and cancer progression.


   II. Coactivator Phosphorylation as the Molecular Basis for Coactivator Specificity
Top
 Abstract
 I. Introduction
 II. Coactivator Phosphorylation...
III. Cellular Signaling,...
 IV. Concluding Remarks
 References
 
During the last decade, it has been noted that the activities of several NRs, including estrogen receptor (ER), progesterone receptor, and androgen receptor, are regulated by posttranslational modifications (37, 38, 39). Prominent among these modifications is receptor phosphorylation elicited by kinase-mediated cellular signaling events. Generally speaking, increased receptor phosphorylation is associated with increased transcriptional activity, and available data indicate that the activity of receptors is subject to regulation by cellular signaling pathways. For example, mutation of the serine118 phosphorylation site of ER{alpha} to an alanine yields a receptor with reduced transcriptional activity (40, 41), whereas induction of ER{alpha}-dependent gene expression by either estradiol- or epidermal growth factor-signaling pathways is associated with increased phosphorylation at this site (42, 43). However, the significance of phosphorylation at serine118 of ER is not without debate. Recently, Font de Mora and Brown (44) reported that phosphorylation of serine118 is not required for epidermal growth factor-induced ER activation, but rather requires phosphorylation of SRC-3 (AIB1). The reason for this discrepancy surrounding serine118 phosphorylation is currently unknown; one possible explanation may involve the strong promoter and cell type specificities of the AF-1 domain (45). Additionally, it is conceivable that other phosphorylation sites on ER and other components of the transcriptional complex may also be required for the activation of ER. To avoid the potential pitfall of transfection and to unequivocally demonstrate its importance, the effects of serine118 phosphorylation on endogenous ER target genes in physiological relevant cell types and settings should be assessed. Despite the fact that the mechanism(s) by which phosphorylation affects transcriptional activity remains obscure, a large number of studies of various NRs support the conclusion that receptor function is subject to regulation by cellular signaling pathways.

In comparison, a realization that the activity and specificity of coactivators is subject to similar regulation has only recently occurred. Of note, SRCs, CBP, and peroxisomal proliferators-activated receptor-{gamma}-coactivator-1 can be modified by phosphorylation as well as other types of modification such as methylation, acetylation, and sumoylation (15, 44, 46, 47, 48, 49, 50, 51, 52, 53, 54). Seven phosphorylation sites for SRC-1 and six for SRC-3 have been identified recently (50, 55). Subsequently, phosphorylation of SRCs was shown to be induced in response to a spectrum of environmental stimuli, including epidermal growth factor, steroid hormones and cytokines, and increased intracellular cAMP (15, 44, 50, 55, 56). Importantly, phosphorylation of SRCs induced by these agents was shown to be essential for their optimal activity. In the case of SRC-1, phosphorylation at threonine1179 and serine1185 induced by cAMP were shown to enhance both ligand-dependent and ligand-independent activity of progesterone receptor (56). Athough the actual underlying mechanism was not defined, phosphorylation was shown to be important for the physical or functional interaction of SRC-1 with p/CAF (p300/CBP associating factor) or CBP (56). Similarly, phosphorylation of SRC-3 induced by epidermal growth factor, steroid hormones, and cytokines also was shown to be important for its coactivator activity (44, 55). Interestingly, phosphorylation of SRC-3 was shown to selectively affect interactions with receptors, NF-{kappa}B, and CBP, but not with CARM1 (55). Taken together, phosphorylation of SRCs seems to be involved in the regulation of protein-protein interactions; however, it is unclear and remains to be investigated whether phosphorylation affects other aspects of SRCs function, such as their intrinsic activation and HAT activities.

Taken together, available data suggest that SRCs are targets of distinct cellular signaling pathways that can regulate coactivator activities. This raised the interesting possibility that SRCs might function to integrate various distinct cellular signals, thereby permitting these signals to accurately and specifically affect a broad range of promoters for transcriptional activation. In support of this, SRCs coactivate an increasingly diverse number of transcription factors (see Section I.B.), and they can be phosphorylated by multiple kinases, such as MAPK and I{kappa}B kinases (IKKs), that are involved in a variety of cellular signaling pathways. Nevertheless, the question remained as to how coactivators might distinguish one downstream class of transcription factors from another, so as to prevent global gene activation in response to phosphorylations induced by a specific pathway.

Interestingly, our recent study on SRC-3 demonstrated that not only is the activity of SRC-3 regulated by phosphorylation, but also the specificity of SRC-3 for different transcription factors can be determined by inducing distinct patterns of phosphorylation on the SRC-3 molecule (55). More specifically, phosphorylation at six amino acids of SRC-3 is shown to be induced by estrogen or androgen hormones, and all six sites are required for ER activation of target genes. However, phosphorylation of only five of these six amino acids is inducible by TNF{alpha}-stimulated signaling pathways and required for coactivation of NF-{kappa}B. In other words, a combination of phosphorylation events at specific sites on SRC-3 affords the coactivator the ability to participate specifically in the stimulation of transcription factor-dependent gene expression (55). It is also important to note that the initiating signal (e.g., estradiol) appropriately stimulates the phosphorylation of SRC-3 so that it is an efficient coactivator for the corresponding transcription factor (e.g., ER{alpha}). This interesting finding suggests that an SRC-3 phosphorylation code exists for distinct regulatory responses to different environmental cues. Although the initial observation was made on SRC-3, it is likely that the activity of other coactivators could be regulated in a similar manner (Fig. 2Go).



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 2. Signaling to SRCs. Kinase-mediated signaling pathways activated by a variety of stimuli, including steroid hormones, cytokines, and growth factors that can communicate with SRCs, are depicted. Although seven major phosphorylation sites (serines372, 395, 517, 569, 1033, 1185 and threonine1179) were identified on SRC-1, it is unclear whether phosphorylation is affected by steroid hormones (as indicated by ?; same is true for SRC-2), and only phosphorylation at threonine1179 and serine1185 induced by cAMP were shown. Therefore, SRC-3 was used as a model molecule because SRC-3 phosphorylation is relatively better understood than SRC-1 and SRC-2. However, it is hypothesized that this same mode of operation from SRC-3 could also apply to SRC-1 and SRC-2 based on the unique function each SRC member has and the poor conservation of identified phosphoamino acids among these members, suggesting that each member might respond differently to stimuli. Although each SRC is able to coactivate with the various receptors in transient transfection assays, the preferred SRC partner for different receptor signaling is connected by an arrow. It is unclear whether phosphorylation of SRCs actually occurs in the cytoplasm or nucleus. These signaling pathways impinge on SRCs by phosphorylating the coactivators on various sites. Importantly, phosphorylation is required for SRC-3 activity, and the specificity of SRC-3 for different transcription factors further depends on where phosphorylation is induced on SRC-3 by a respective stimulus. It is proposed that a specific phosphorylation-dependent code allows SRC-3 to activate gene expression specifically and accurately. Notably, it is envisioned that signaling to SRCs is important not only for their normal physiological functions but also could have detrimental effects if aberrant activation of SRC-3 by these signaling pathways occurs. P1, pT24; P2, pS505; P3, pS543; P4, pS857; P5, pS860; P6, pS867. Pg, Progesterone; Dex, dexamethasone; E2, estradiol; GR, glucocorticoid receptor; PR, progesterone receptor.

 
Although all three SRCs contain both redundant and distinct functions, it is clear from experiments in mice that each individual SRC contains the capacity to regulate different biological functions. To date, the molecular basis underpinning these fundamental differences was unclear. Several recent notable differences were observed among SRCs that shed new light on this issue. For example, the IKK complex was copurified exclusively with SRC-3 but not SRC-1 and, accordingly, phosphorylation of SRC-3, but not SRC-1, is enhanced in response to TNF{alpha} stimulation (15). This suggests that the activity of SRCs may be modulated by the signaling pathways that control the activity of the transcription factors with which they are associated. Second, comparison of the identified phosphoamino acids revealed very little conservation of these sequences among SRCs, both with respect to positions and type of phosphorylation sites (50, 55), arguing that phosphorylation is a significant determinant of the ultimate specificity of SRCs. Finally, among the steroid hormones tested, we found that only ligands for ER (estradiol) and androgen receptor (R1881), but not progesterone receptor (progesterone), can induce SRC-3 phosphorylation on the identified sites (R. C. Wu and B. W. O’Malley, unpublished results). Consistent with earlier findings (57), these results clearly demonstrated a biochemical degree of ligand, receptor, and coactivator specificity. Thus, we conclude that posttranslational phosphorylation provides a molecular basis that determines the ability of SRCs to distinguish among various NRs and other transcription factors to provide specific responses to distinct upstream signaling pathways (Fig. 2Go).


   III. Cellular Signaling, Coactivator Phosphorylation, and Cancer
Top
 Abstract
 I. Introduction
 II. Coactivator Phosphorylation...
 III. Cellular Signaling,...
IV. Concluding Remarks
 References
 
The gene for SRC-3 (also known as AIB1 for amplified in breast cancer-1) has been shown to be amplified in 10% of human breast tumors, and the same report indicated that elevated SRC-3 mRNA expression was found for 64% of tumors (58); this was the first indication that SRC-3 may confer some growth advantage. Subsequently, it was shown that SRC-3 overexpression enhances somatic cell growth in prostate cancer cells by activating the AKT signaling pathway (59). In addition, overexpression of SRC-3 in mice alone or in the presence of the Ras oncogene facilitates mammary gland tumorgenesis, and this is associated with increasing serum levels of IGF-I and AKT pathway activity (60, 61). Conversely, knockout of the SRC-3 gene reduced adult body size, due in part to lower circulating IGF-I levels and impairment of IGF-I signaling (36). Collectively, these studies demonstrate that SRC-3 alone is sufficient for the initiation of tumorgenesis, and SRC-3 also can function as a facilitator in the oncogenesis process. It is clearly an oncogene.

However, the levels of SRC-3 protein are not always the sole determinants of SRC-3 pathological function. As summarized above, SRC-3 is an integral and important component of cellular signaling pathways, suggesting a means by which its activity can be subject to other levels of regulation (15, 35, 44, 55). For example, MAPK and IKK signaling both augment SRC-3 activity by phosphorylating SRC-3. As these kinases are important regulators of cellular growth functions, it is evident that aberrant activation of SRC-3 by these kinases could have adverse effects. Therefore, to fully appreciate the function of SRC-3, it is paramount to account for the milieu of cellular signaling in context with SRC-3. However, it is of note that the mechanisms involved in the induction of SRC-3 phosphorylation appear to be complex in nature. First of all, an array of kinases was shown to be able to phosphorylate SRC-3 at least in vitro, and some of the same amino acids of SRC-3 are potential targets of different kinases. Although it broadens and supports the ever-expanding role of SRC-3 in diverse signaling events, it also raises an interesting question as to how different kinases are able to act in concert to phosphorylate and activate SRC-3 in response to a single type of stimulation. Second, it is unclear as to the location where phosphorylation of SRC-3 actually takes place, i.e., in the cytoplasm or in the nucleus where transcription occurs, or in both compartments. Given the fact that the NRs, SRC-3, and the kinases involved are present in both the cytoplasm and nucleus, and are able to shuttle back and forth between these two compartments, this issue proves to be difficult to answer definitively. Lastly, some of the kinases, such as MAPK, were shown to phosphorylate not only SRC-3, but the receptors as well. It is not clear whether phosphorylation of one will affect phosphorylation of the other, or whether there is a sequential order for the phosphorylation of these proteins. Despite all of these unanswered questions, it should not lessen our interest to better understand how and where the signaling cascade originates. Experiments using specific mutants of receptors and SRC-3 should be useful for answering these remaining questions.

As several studies have established SRC-3 as a bona fide oncogene, it also is noteworthy to point out that despite the significant progress made in treating endocrine-sensitive cancers, success is still severely hampered by the development of therapeutic resistance. Therefore, it is imperative to fully understand the underlying mechanisms responsible for the acquisition of this resistance. Perhaps the best studied example of this is the development of resistance to tamoxifen therapy in the progression of human breast cancer. It was proposed, based on work done in the mid-1990s (62, 63) that the relative expression of coactivators and corepressors in a given cell would be critical determinants of the biocharacter (e.g., agonist vs. antagonist activity) of selective receptor modulators such as the selective ER modulator, tamoxifen. Evidence accumulated since that time has supported that hypothesis, including demonstrations that coactivators promote tamoxifen agonist activity (62, 63, 64) and corepressors are important for the antagonistic activity of this widely used drug (65, 66). However, varied cellular signaling pathways (including phosphorylation, acetylation, sumoylation, and methylation) can exert distinct effects on NR and coregulator function and suggest that the intracellular environment also can play a significant role in determining the biological activity of selective receptor modulators such as tamoxifen (reviewed in Ref. 67). Of the recently delineated cellular pathways potentially contributing to this resistance, the cross-talk between NRs and the growth-/survival-promoting signaling pathways seems to hold much promise, particularly as it has become increasingly evident that the interaction between these different pathways occurs at multiple levels, involving both NRs and coactivators (42, 44, 55, 68). Thus, as another layer of complexity has been added to the NR-coactivator picture, the recent data suggest coactivators as viable and critical targets for therapeutic intervention.

As an interesting example, the oncogenic potential of SRC-3 was recently demonstrated to be closely associated with the phosphorylation state of SRC-3 in vitro (55), consistent with the ability of cellular signaling events to modulate SRC-3 activity. In a recent study of breast cancer patients, high SRC-3 (AIB1) expression in patients who had not received adjuvant tamoxifen therapy was associated with improved disease-free survival, especially for those patients who also had low expression levels of HER-2/neu receptor tyrosine kinase (69). However, in patients that had received tamoxifen treatment, those with overexpression of SRC-3 in conjunction with high HER-2/neu expression levels experienced a significantly reduced period of disease-free survival, suggesting that cross-talk between these two pathways is disadvantageous. In a follow-up in vitro study, overexpression of HER-2/neu was associated with 1) increased phosphorylation of SRC-3 in response to stimulating breast cancer cells with heregulin, estradiol or tamoxifen, and 2) increased tamoxifen-induced association of SRC-3 with a gene promoter and elevated tamoxifen stimulation of ER target gene expression (70). These findings add another dimension to our understanding of SRC-3 function and exemplify the importance of cellular signaling as an integral part of coactivator biology. Moreover, these considerations present an interesting scenario whereby aberrant signaling activation of SRC-3 contributes to tumorgenesis and/or development of resistance to hormone therapy in endocrine cancers, suggesting a platform for future experimentation and drug development.


   IV. Concluding Remarks
Top
 Abstract
 I. Introduction
 II. Coactivator Phosphorylation...
 III. Cellular Signaling,...
 IV. Concluding Remarks
References
 
As our understanding of the biology of NRs and coactivators increases, so does our appreciation of the complexity of their actions. Even with recent developments, a number of important questions remain to be addressed, and future efforts should be oriented toward providing a better understanding of a number of these issues.

First of all, the nature of receptor specificity and functional redundancy of each of the SRC members remains an interesting topic to many in the field. Although the spatial expression of SRC family members in different cell types contributes to selectivity, it remains to be determined what other factors contribute to their specificity. Here we hypothesize, as shown in the case of NRs and NF-{kappa}B, that differential posttranslational modifications of SRC members help to determine their receptor specificity. A detailed examination of all types of modifications, including phosphorylation, acetylation, methylation, ubiquitination, neddylation, and sumoylation, will expand our knowledge and provide new insight into this matter. Second, although SRC-3 was demonstrated to be an oncogene, the exact role of SRC-3 in tumor initiation must be further characterized. Examination of additional signaling upstream of SRC-3 activation and subsequent downstream genetic events elicited by SRC-3 activation deserve equal attention. Finally, because the oncogenic potential of SRC-3 has been linked to its phosphorylation state, it is likely that aberrant phosphorylation and activation of SRC-3 will be linked to advanced stages of cancers. Therefore, whether assessment of a hyperphosphorylation state or phosphorylation of specific amino acids of SRC-3 can be used as a marker for tumor progression is a question begging further investigation, and it is possible that management of disease in the future will encompass not only therapies targeted to NRs, but also to the coregulators that are so critical for mediating their biological activity within the cell.


   Acknowledgments
 
We apologize to our colleagues whose work could not be cited due to page limitation.


   Footnotes
 
This work was supported by a postdoctoral fellowship from the Department of Defense (to R.-C.W.), National Institutes of Health (NIH) Grants DK53002 and DK64083 (to C.L.S.), and NIH Grants HD08818, HD07857, and NIDDK/NURSA-5U19DK62434-02 (to B.W.O.).

First Published Online April 6, 2005

Abbreviations: AF, Activation function; AIB1, amplified in breast cancer 1; CARM1, coactivator-associated arginine methyltransferase-1; CBP, cAMP response element-binding protein (CREB)-binding protein; ER, estrogen receptor; HAT, histone acetyltransferase; IKK, I{kappa}B kinase; NF-{kappa}B, nuclear factor-{kappa}B; NR, nuclear receptor; SRC, steroid receptor coactivator.


   References
Top
 Abstract
 I. Introduction
 II. Coactivator Phosphorylation...
 III. Cellular Signaling,...
 IV. Concluding Remarks
 References
 

  1. Tsai M-J, O’Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 63:451–486[CrossRef][Medline]
  2. Evans RM 1988 The steroid and thyroid hormone receptor superfamily. Science 240:889–895[Abstract/Free Full Text]
  3. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121–141[Free Full Text]
  4. McKenna NJ, O’Malley BW 2002 Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108:465–474[CrossRef][Medline]
  5. Leo C, Chen JD 2000 The SRC family of nuclear receptor coactivators. Gene 245:1–11[CrossRef][Medline]
  6. Xu J, Li Q 2003 Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 17:1681–1692[Abstract/Free Full Text]
  7. Huang ZJ, Edery I, Rosbash M 1993 PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature 364:259–262[CrossRef][Medline]
  8. Belandia B, Parker MG 2000 Functional interaction between the p160 coactivator proteins and the transcriptional enhancer factor family of transcription factors. J Biol Chem 275:30801–30805[Abstract/Free Full Text]
  9. Chen SL, Dowhan DH, Hosking BM, Muscat GE 2000 The steroid receptor coactivator, GRIP-1, is necessary for MEF-2C-dependent gene expression and skeletal muscle differentiation. Genes Dev 14:1209–1228[Abstract/Free Full Text]
  10. Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW 1998 Steroid receptor coactivator-1 coactivates activating protein-1- mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273:16651–16654[Abstract/Free Full Text]
  11. Arimura A, Van Peer M, Schroeder AJ, Rothman P 2004 The transcriptional co-activator p/CIP (NCoA-3) is upregulated by STAT6 and serves as a positive regulator of transcriptional activation by STAT6. J Biol Chem 279:31105–31112[Abstract/Free Full Text]
  12. Lee SK, Kim HJ, Kim JW, Lee JW 1999 Steroid receptor coactivator-1 and its family members differentially regulate transactivation by the tumor suppressor protein p53. Mol Endocrinol 13:1924–1933[Abstract/Free Full Text]
  13. Na SY, Lee SK, Han SJ, Choi HS, Im SY, Lee JW 1998 Steroid receptor coactivator-1 interacts with the p50 subunit and coactivates nuclear factor {kappa}B-mediated transactivations. J Biol Chem 273:10831–10834[Abstract/Free Full Text]
  14. Werbajh S, Nojek I, Lanz R, Costas MA 2000 RAC-3 is a NF-{kappa}B coactivator. FEBS Lett 485:195–199[CrossRef][Medline]
  15. Wu RC, Qin J, Hashimoto Y, Wong J, Xu J, Tsai SY, Tsai M-J, O’Malley BW 2002 Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I{kappa}B kinase. Mol Cell Biol 22:3549–3561[Abstract/Free Full Text]
  16. Litterst CM, Kliem S, Marilley D, Pfitzner E 2003 NCoA-1/SRC-1 is an essential coactivator of STAT5 that binds to the FDL motif in the {alpha}-helical region of the STAT5 transactivation domain. J Biol Chem 278:45340–45351[Abstract/Free Full Text]
  17. Litterst CM, Pfitzner E 2002 An LXXLL motif in the transactivation domain of STAT6 mediates recruitment of NCoA-1/SRC-1. J Biol Chem 277:36052–36060[Abstract/Free Full Text]
  18. Louie MC, Zou JX, Rabinovich A, Chen HW 2004 ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol Cell Biol 24:5157–5171[Abstract/Free Full Text]
  19. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai M-J, Edwards DP, O’Malley BW 1998 The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 273:12101–12108[Abstract/Free Full Text]
  20. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17:507–519[CrossRef][Medline]
  21. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733–736[CrossRef][Medline]
  22. Voegel JJ, Heine MJ, Zechel C, Chambon P, Gronemeyer H 1996 TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667–3675[Medline]
  23. Li J, O’Malley BW, Wong J 2000 p300 Requires its histone acetyltransferase activity and SRC-1 interaction domain to facilitate thyroid hormone receptor activation in chromatin. Mol Cell Biol 20:2031–2042[Abstract/Free Full Text]
  24. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580[CrossRef][Medline]
  25. Chen D, Ma H, Hong H, Koh SS, Huang SM, Schurter BT, Aswad DW, Stallcup MR 1999 Regulation of transcription by a protein methyltransferase. Science 284:2174–2177[Abstract/Free Full Text]
  26. Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, McKenna NJ, Onate SA, Tsai SY, Tsai M-J, O’Malley BW 1997 Steroid receptor coactivator-1 is a histone acetyltransferase. Nature 389:194–198[CrossRef][Medline]
  27. Kurokawa R, Kalafus D, Ogliastro MH, Kioussi C, Xu L, Torchia J, Rosenfeld MG, Glass CK 1998 Differential use of CREB binding protein-coactivator complexes. Science 279:700–703[Abstract/Free Full Text]
  28. Smith CL, Onate SA, Tsai M-J, O’Malley BW 1996 CREB binding protein acts synergistically with steroid receptor coactivator-1 to enhance steroid receptor-dependent transcription. Proc Natl Acad Sci USA 93:8884–8888[Abstract/Free Full Text]
  29. Torchia J, Rose DW, Inostroza J, Kamei Y, Westin S, Glass CK, Rosenfeld MG 1997 The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. Nature 387:677–684[CrossRef][Medline]
  30. Cavarretta IT, Mukopadhyay R, Lonard DM, Cowsert LM, Bennett CF, O’Malley BW, Smith CL 2002 Reduction of coactivator expression by antisense oligodeoxynucleotides inhibits ER{alpha} transcriptional activity and MCF-7 proliferation. Mol Endocrinol 16:253–270[Abstract/Free Full Text]
  31. Shao W, Keeton EK, McDonnell DP, Brown M 2004 Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proc Natl Acad Sci USA 101:11599–11604[Abstract/Free Full Text]
  32. Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai M-J, O’Malley BW 1998 Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279:1922–1925[Abstract/Free Full Text]
  33. Gehin M, Mark M, Dennefeld C, Dierich A, Gronemeyer H, Chambon P 2002 The function of TIF2/GRIP1 in mouse reproduction is distinct from those of SRC-1 and p/CIP. Mol Cell Biol 22:5923–5937[Abstract/Free Full Text]
  34. Picard F, Gehin M, Annicotte J, Rocchi S, Champy MF, O’Malley BW, Chambon P, Auwerx J 2002 SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111:931–941[CrossRef][Medline]
  35. Wang Z, Rose DW, Hermanson O, Liu F, Herman T, Wu W, Szeto D, Gleiberman A, Krones A, Pratt K, Rosenfeld R, Glass CK, Rosenfeld MG 2000 Regulation of somatic growth by the p160 coactivator p/CIP. Proc Natl Acad Sci USA 97:13549–13554[Abstract/Free Full Text]
  36. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O’Malley BW 2000 The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci USA 97:6379–6384[Abstract/Free Full Text]
  37. Gioeli D, Ficarro SB, Kwiek JJ, Aaronson D, Hancock M, Catling AD, White FM, Christian RE, Settlage RE, Shabanowitz J, Hunt DF, Weber MJ 2002 Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J Biol Chem 277:29304–29314[Abstract/Free Full Text]
  38. Lannigan DA 2003 Estrogen receptor phosphorylation. Steroids 68:1–9[CrossRef][Medline]
  39. Weigel NL 1996 Steroid hormone receptors and their regulation by phosphorylation. Biochem J 319:657–667
  40. Le Goff P, Montano MM, Schodin DJ, Katzenellenbogen BS 1994 Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem 269:4458–4466[Abstract/Free Full Text]
  41. Ali S, Metzger D, Bornert JM, Chambon P 1993 Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J 12:1153–1160[Medline]
  42. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P 1995 Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270:1491–1494[Abstract/Free Full Text]
  43. Bunone G, Briand PA, Miksicek RJ, Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 15:2174–2183[Medline]
  44. Font de Mora J, Brown M 2000 AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 20:5041–5047[Abstract/Free Full Text]
  45. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P, Parker MG, Stein RB, Pike JW, McDonnell DP 1994 Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol 8:21–30[Abstract]
  46. Chevillard-Briet M, Trouche D, Vandel L 2002 Control of CBP co-activating activity by arginine methylation. EMBO J 21:5457–5466[CrossRef][Medline]
  47. Chauchereau A, Amazit L, Quesne M, Guiochon-Mantel A, Milgrom E 2003 Sumoylation of the progesterone receptor and of the steroid receptor coactivator SRC-1. J Biol Chem 278:12335–12343[Abstract/Free Full Text]
  48. Chen H, Lin RJ, Xie W, Wilpitz D, Evans RM 1999 Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98:675–686[CrossRef][Medline]
  49. Kotaja N, Karvonen U, Janne OA, Palvimo JJ 2002 The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J Biol Chem 277:30283–30288[Abstract/Free Full Text]
  50. Rowan BG, Weigel NL, O’Malley BW 2000 Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J Biol Chem 275:4475–4483[Abstract/Free Full Text]
  51. See RH, Calvo D, Shi Y, Kawa H, Luke MP, Yuan Z 2001 Stimulation of p300-mediated transcription by the kinase MEKK1. J Biol Chem 276:16310–16317[Abstract/Free Full Text]
  52. Puigserver P, Rhee J, Lin J, Wu Z, Yoon JC, Zhang CY, Krauss S, Mootha VK, Lowell BB, Spiegelman BM 2001 Cytokine stimulation of energy expenditure through p38 MAP kinase activation of PPAR{gamma} coactivator-1. Mol Cell 8:971–982[CrossRef][Medline]
  53. Yang W, Hong YH, Shen XQ, Frankowski C, Camp HS, Leff T 2001 Regulation of transcription by AMP-activated protein kinase: phosphorylation of p300 blocks its interaction with nuclear receptors. J Biol Chem 276:38341–38344[Abstract/Free Full Text]
  54. Lopez GN, Turck CW, Schaufele F, Stallcup MR, Kushner PJ 2001 Growth factors signal to steroid receptors through mitogen-activated protein kinase regulation of p160 coactivator activity. J Biol Chem 276:22177–22182[Abstract/Free Full Text]
  55. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai M-J, O’Malley BW 2004 Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell 15:937–949[CrossRef][Medline]
  56. Rowan BG, Garrison N, Weigel NL, O’Malley BW 2000 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol Cell Biol 20:8720–8730[Abstract/Free Full Text]
  57. Li X, Wong J, Tsai SY, Tsai M-J, O’Malley BW 2003 Progesterone and glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns of local chromatin modification. Mol Cell Biol 23:3763–3773[Abstract/Free Full Text]
  58. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM, Meltzer PS 1997 AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968[Abstract/Free Full Text]
  59. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai M-J 2003 Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol 23:7742–7755[Abstract/Free Full Text]
  60. Kuang SQ, Liao L, Zhang H, Lee AV, O’Malley BW, Xu J 2004 AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res 64:1875–1885[Abstract/Free Full Text]
  61. Torres-Arzayus MI, De Mora JF, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, Brown M 2004 High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263–274[CrossRef][Medline]
  62. Smith CL, Nawaz Z, O’Malley BW 1997 Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed anti- estrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657–666[Abstract/Free Full Text]
  63. Jackson TA, Richer JK, Bain DL, Takimoto GS, Tung L, Horwitz KB 1997 The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT. Mol Endocrinol 11:693–705[Abstract/Free Full Text]
  64. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465–2468[Abstract/Free Full Text]
  65. Huang HJ, Norris JD, McDonnell DP 2002 Identification of a negative regulatory surface within estrogen receptor {alpha} provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists. Mol Endocrinol 16:1778–1792[Abstract/Free Full Text]
  66. Jepsen K, Hermanson O, Onami TM, Gleiberman AS, Lunyak V, McEvilly RJ, Kurokawa R, Kumar V, Liu F, Seto E, Hedrick SM, Mandel G, Glass CK, Rose DW, Rosenfeld MG 2000 Combinatorial roles of the nuclear receptor corepressor in transcription and development. Cell 102:753–763[CrossRef][Medline]
  67. Smith CL, O’Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr Rev 25:45–71[Abstract/Free Full Text]
  68. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, Del-Rio AL, Ricote M, Ngo S, Gemsch J, Hilsenbeck SG, Osborne K, Glass CK, Rosenfeld MG, Rose DW 1998 Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95:2920–2925[Abstract/Free Full Text]
  69. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361[Abstract/Free Full Text]
  70. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R 2004 Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926–935[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 FASEB J.Home page
A. G. Atanasov, D. Leiser, C. Roesselet, M. Noti, N. Corazza, K. Schoonjans, and T. Brunner
Cell cycle-dependent regulation of extra-adrenal glucocorticoid synthesis in murine intestinal epithelial cells
FASEB J, December 1, 2008; 22(12): 4117 - 4125.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
R. Narayanan, C. C. Coss, M. Yepuru, J. D. Kearbey, D. D. Miller, and J. T. Dalton
Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways
Mol. Endocrinol., November 1, 2008; 22(11): 2448 - 2465.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
I. S. Fenne, T. Hoang, M. Hauglid, J. V. Sagen, E. A. Lien, and G. Mellgren
Recruitment of Coactivator Glucocorticoid Receptor Interacting Protein 1 to an Estrogen Receptor Transcription Complex Is Regulated by the 3',5'-Cyclic Adenosine 5'-Monophosphate-Dependent Protein Kinase
Endocrinology, September 1, 2008; 149(9): 4336 - 4345.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z. Hammoud, B. Tan, S. Badve, and R. M Bigsby
Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma
Endocr. Relat. Cancer, June 1, 2008; 15(2): 475 - 483.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Naughton, K. MacLeod, B. Kuske, R. Clarke, D. A. Cameron, and S. P. Langdon
Progressive Loss of Estrogen Receptor {alpha} Cofactor Recruitment in Endocrine Resistance
Mol. Endocrinol., November 1, 2007; 21(11): 2615 - 2626.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
N. L. Weigel and N. L. Moore
Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions
Mol. Endocrinol., October 1, 2007; 21(10): 2311 - 2319.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. M. Lonard, R. B. Lanz, and B. W. O'Malley
Nuclear Receptor Coregulators and Human Disease
Endocr. Rev., August 1, 2007; 28(5): 575 - 587.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev., June 1, 2007; 28(4): 387 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
A. McMaster and D. W. Ray
Modelling the glucocorticoid receptor and producing therapeutic agents with anti-inflammatory effects but reduced side-effects
Exp Physiol, March 1, 2007; 92(2): 299 - 309.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Sanchez, K. Sauve, N. Picard, and A. Tremblay
The Hormonal Response of Estrogen Receptor beta Is Decreased by the Phosphatidylinositol 3-Kinase/Akt Pathway via a Phosphorylation-dependent Release of CREB-binding Protein
J. Biol. Chem., February 16, 2007; 282(7): 4830 - 4840.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. Handschin and B. M. Spiegelman
Peroxisome Proliferator-Activated Receptor {gamma} Coactivator 1 Coactivators, Energy Homeostasis, and Metabolism
Endocr. Rev., December 1, 2006; 27(7): 728 - 735.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J.-F. Louet, A. Coste, L. Amazit, M. Tannour-Louet, R.-C. Wu, S. Y. Tsai, M.-J. Tsai, J. Auwerx, and B. W. O'Malley
Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program
PNAS, November 21, 2006; 103(47): 17868 - 17873.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y.-S. Keum, S. Yu, P. P.-J. Chang, X. Yuan, J.-H. Kim, C. Xu, J. Han, A. Agarwal, and A.-N. T. Kong
Mechanism of Action of Sulforaphane: Inhibition of p38 Mitogen-Activated Protein Kinase Isoforms Contributing to the Induction of Antioxidant Response Element-Mediated Heme Oxygenase-1 in Human Hepatoma HepG2 Cells.
Cancer Res., September 1, 2006; 66(17): 8804 - 8813.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. M. Garcia-Pedrero, E. Kiskinis, M. G. Parker, and B. Belandia
The SWI/SNF Chromatin Remodeling Subunit BAF57 Is a Critical Regulator of Estrogen Receptor Function in Breast Cancer Cells
J. Biol. Chem., August 11, 2006; 281(32): 22656 - 22664.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Wu, L. Sun, Y. Zhang, Y. Chen, B. Shi, R. Li, Y. Wang, J. Liang, D. Fan, G. Wu, et al.
Coordinated Regulation of AIB1 Transcriptional Activity by Sumoylation and Phosphorylation
J. Biol. Chem., August 4, 2006; 281(31): 21848 - 21856.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B.-S. An, D. M. Selva, G. L. Hammond, A. Rivero-Muller, N. Rahman, and P. C. K. Leung
Steroid Receptor Coactivator-3 Is Required for Progesterone Receptor Trans-activation of Target Genes in Response to Gonadotropin-releasing Hormone Treatment of Pituitary Cells
J. Biol. Chem., July 28, 2006; 281(30): 20817 - 20824.
[Abstract] [Full Text] [PDF]